Federal multidistrict litigation tracker

MDL 3140 Update — Depo-Provera Lawsuit

In re: Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation. Counts are monthly JPML snapshots and can change between reports.

Lawsuit status — October 2026

Depo-Provera Lawsuit

Verified October 11, 2026

MDL: MDL-3140
Court: N.D. Fla.
Judge: Judge M. Casey Rodgers
Pending cases: 6,412; Count as of October 1, 2026 · Source; +9 since prior report
Current phase: Settlement registration; litigation continues for remaining claims
Settlement status: active — individual eligibility required
Latest development: JPML reports 6,412 pending actions in MDL-3140 on October 1, 2026, up 9 from 6,403 on September 1; 6,524 total historical actions are reported separately.
Next major event: November 30, 2026 — Settlement registration deadline

What changed this month?

●JPML reports 6,412 pending actions in MDL-3140 on October 1, 2026, up 9 from 6,403 on September 1; 6,524 total historical actions are reported separately. Source
●September 4 orders appoint a supplemental compensation fund allocation master (CMO 15), a qualified settlement fund administrator (CMO 16) and a lien resolution master (CMO 17). The orders page reviewed October 11 shows no Rule 702 ruling and lists a December 18 case management conference. Source
●JPML reports 6,403 pending actions on September 1, 2026, compared with 6,294 on August 3; 6,510 total historical actions are reported separately. Source
●The court calendar listed a September 18 Rule 702 hearing for ongoing litigation; the public orders page reviewed September 25 does not state an outcome. Source
●The August 5 CMO 13 appoints BrownGreer PLC as settlement administrator to review records and determine eligibility. Source

MDL details

Created: February 7, 2025
Pending: 6,412
Total actions filed: 6,524
Monthly change: +9

Defendants named in the tracked record

Pfizer Inc.; Pharmacia & Upjohn Co. LLC; Pharmacia LLC. Defendants dispute the allegations.

Historical case counts

Report	Pending	Total filed
October 1, 2026	6,412	6,524
September 1, 2026	6,403	6,510
August 3, 2026	6,294	6,394
July 1, 2026	5,830	—

What the litigation alleges

The tracked claims concern prescription drug injury claim, including meningioma brain tumors. These are allegations; defendants dispute liability and causation.

Stage and bellwether status

Court orders confirm a private settlement program documented in July 2026. CMO 13 appoints BrownGreer as administrator, and CMO 14 identifies November 30, 2026 as the registration deadline. CMO 12 states that the original December Pilot trial was canceled. The court calendar listed a September 18 Rule 702 hearing for ongoing litigation; the public orders page reviewed October 11 does not state an outcome. Eligibility and payments are not automatic.

Bellwether record: CMO 12 states the original Pilot schedule was vacated and the December trial canceled following the settlement announcement.

Settlement status

Court orders confirm a confidential settlement program for eligible Depo-Provera claims, with BrownGreer appointed administrator on August 5, 2026. CMO 14 identifies November 30, 2026 as the registration deadline. The public orders reviewed October 11 do not disclose an aggregate fund or individual payout grid. This is a private agreement, not a class settlement requiring a fairness hearing. Nonparticipating and ineligible claims continue under court procedures.

Individual claims: Court orders confirm a confidential settlement program for eligible Depo-Provera claims, with BrownGreer appointed administrator on August 5, 2026. CMO 14 identifies November 30, 2026 as the registration deadline. The public orders reviewed October 11 do not disclose an aggregate fund or individual payout grid. This is a private agreement, not a class settlement requiring a fairness hearing. Nonparticipating and ineligible claims continue under court procedures.